Michael Brandon Ware
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Brandon Ware has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Gregory B. Lesinski
Emory University
19 shared publications - Hannah M. Knochelmann
Medical University of South Carolina
17 shared publications - Chrystal M. Paulos
Winship Cancer Institute, Emory University
16 shared publications - Amalia M. Rivera Reyes
Winship Cancer Institute, Emory University, Atlanta, Georgia
15 shared publications - Anna C. Cole
Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia
15 shared publications - Aubrey S. Smith
Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia
15 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 9: Viability (A) Representative flow plots showing viability of cells in the lymph node of mice given FTY720 or no treatment. Gated on Lymphocytes/Single Cells. (B) Bar graph of viability for all samples. Mann Whitney test performed (p=0.5476).
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 9: Viability (A) Representative flow plots showing viability of cells in the lymph node of mice given FTY720 or no treatment. Gated on Lymphocytes/Single Cells. (B) Bar graph of viability for all samples. Mann Whitney test performed (p=0.5476).
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Table of reagent information and antibodies used.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Table of reagent information and antibodies used.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 7: Assessment of pmel-1 T cell phenotype prior to adoptive transfer (A) CD8 expression histogram on unstained, bulk pmel-1 cells, or sorted naïve pmel-1 T cells. Gated on lymphocytes/single cell/live/CD45+ (B) Expression of surface markers CD44, CD62L, ICOS, Tim-3, PD-1, and CD69 on unstained, bulk pmel-1 T cells, or sorted naïve pmel-1 T cells prior to adoptive transfer. Gated on Lymphocytes/Single Cells/Live/CD45+/Vβ13+ Thy1.1+. (C) Expression of intracellular markers TCF-1 and Ki-67 expression on unstained, bulk pmel-1 T cells, or naïve pmel-1 T cells prior to adoptive transfer.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 7: Assessment of pmel-1 T cell phenotype prior to adoptive transfer (A) CD8 expression histogram on unstained, bulk pmel-1 cells, or sorted naïve pmel-1 T cells. Gated on lymphocytes/single cell/live/CD45+ (B) Expression of surface markers CD44, CD62L, ICOS, Tim-3, PD-1, and CD69 on unstained, bulk pmel-1 T cells, or sorted naïve pmel-1 T cells prior to adoptive transfer. Gated on Lymphocytes/Single Cells/Live/CD45+/Vβ13+ Thy1.1+. (C) Expression of intracellular markers TCF-1 and Ki-67 expression on unstained, bulk pmel-1 T cells, or naïve pmel-1 T cells prior to adoptive transfer.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 4: Assessing differences between B16KVP and B16F10 in the absence of ACT. (A) Volcano plot depicting differentially expressed genes in the tumors of mice with neoantigen (B16KVP) versus wild-type (B16F10) tumors in the absence of ACT (n=5 mice/group). Red lines depict a p-value of 0.05 and log2 fold change of ± 0.05. (B) Top significantly enriched genes in the B16KVP NT mice compared to the B16F10 NT. (C) Pathway analysis of significantly upregulated genes enriched in the B16KVP-tumored mice. GO enrichment analysis, biological pathways used. (D) For genes shared between the B16KVP + ACT versus B16F10 + ACT comparison and B16KVP NT versus B16F10 NT comparisons, the relative expression was evaluated (E) Individual tumor curves of mice bearing B16F10 or B16KVP tumors and administered either isotype or anti-PD-1 antibody on days 7, 10, 14, 17, 21, and 24 (n=5-10 mice/group).
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 4: Assessing differences between B16KVP and B16F10 in the absence of ACT. (A) Volcano plot depicting differentially expressed genes in the tumors of mice with neoantigen (B16KVP) versus wild-type (B16F10) tumors in the absence of ACT (n=5 mice/group). Red lines depict a p-value of 0.05 and log2 fold change of ± 0.05. (B) Top significantly enriched genes in the B16KVP NT mice compared to the B16F10 NT. (C) Pathway analysis of significantly upregulated genes enriched in the B16KVP-tumored mice. GO enrichment analysis, biological pathways used. (D) For genes shared between the B16KVP + ACT versus B16F10 + ACT comparison and B16KVP NT versus B16F10 NT comparisons, the relative expression was evaluated (E) Individual tumor curves of mice bearing B16F10 or B16KVP tumors and administered either isotype or anti-PD-1 antibody on days 7, 10, 14, 17, 21, and 24 (n=5-10 mice/group).
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 5: Serum cytokines are not different at baseline in neoantigen versus wild-type-tumored mice. All mice were given either B16KVP or B16F10 tumors. Six days later, mice received 5 Gy TBI. The next day, mice did or did not receive naïve pmel-1 ACT. Five days later, serum was collected. (A) Comparison of serum cytokines in B16KVP versus B16F10-tumored mice without addition of ACT. Multiple Mann-Whitney tests were performed – Unpaired, Nonparametric Mann-Whitney test with corrections for multiple comparisons using the Holm-Sidak Method. P-value threshold of 0.05 was set. (NS denotes not significant, p-value > 0.05). (B) Heatmap depicting serum cytokine data of B16KVP and B16F10-tumored mice at baseline as well as with ACT.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 5: Serum cytokines are not different at baseline in neoantigen versus wild-type-tumored mice. All mice were given either B16KVP or B16F10 tumors. Six days later, mice received 5 Gy TBI. The next day, mice did or did not receive naïve pmel-1 ACT. Five days later, serum was collected. (A) Comparison of serum cytokines in B16KVP versus B16F10-tumored mice without addition of ACT. Multiple Mann-Whitney tests were performed – Unpaired, Nonparametric Mann-Whitney test with corrections for multiple comparisons using the Holm-Sidak Method. P-value threshold of 0.05 was set. (NS denotes not significant, p-value > 0.05). (B) Heatmap depicting serum cytokine data of B16KVP and B16F10-tumored mice at baseline as well as with ACT.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Table S1: Table containing all statistically significant (p <0.05) genes detected 5 days post-ACT from tumor tissue comparing mice with B16KVP to B16F10 tumors that received pmel-1 ACT.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Table S1: Table containing all statistically significant (p <0.05) genes detected 5 days post-ACT from tumor tissue comparing mice with B16KVP to B16F10 tumors that received pmel-1 ACT.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 2: Pmel-1 T cells bind more tightly to B16KVP compared to B16F10 cells. The immune synapse binding avidity of naïve pmel-1 T cell isolates to B16F10 and B16KVP were assessed via acoustic force microscopy. (A) The force ramp is plotted showing the fraction of T cells bound as the force ramp increases. (B) The area under the curve (AUC) of the fraction of T cells bound during the force ramp from (A) is plotted.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 2: Pmel-1 T cells bind more tightly to B16KVP compared to B16F10 cells. The immune synapse binding avidity of naïve pmel-1 T cell isolates to B16F10 and B16KVP were assessed via acoustic force microscopy. (A) The force ramp is plotted showing the fraction of T cells bound as the force ramp increases. (B) The area under the curve (AUC) of the fraction of T cells bound during the force ramp from (A) is plotted.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 1: Quality assurance by flow cytometry of naïve cytotoxic T cells prior to adoptive transfer to mice bearing melanoma. (A) Gating Strategy for isolating lymphocytes followed by selection of singlets and subsequently live cells (B) Double positive Vβ13+ Thy1.1+ cells were gated on live cells (C) CD44 and CD62L characterization of Vβ13+ Thy1.1+ was used to assess efficacy of naïve T cell isolation (>94% yield).
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 1: Quality assurance by flow cytometry of naïve cytotoxic T cells prior to adoptive transfer to mice bearing melanoma. (A) Gating Strategy for isolating lymphocytes followed by selection of singlets and subsequently live cells (B) Double positive Vβ13+ Thy1.1+ cells were gated on live cells (C) CD44 and CD62L characterization of Vβ13+ Thy1.1+ was used to assess efficacy of naïve T cell isolation (>94% yield).
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 6: Characterizing host immune cells in neoantigen versus wild-type tumors. (A) Breakdown of immune cells within B16KVP or B16F10 subcutaneous tumors (average taken of n=5). All mice were given either B16KVP or B16F10 tumors. Mice received TBI but no ACT. Five days later, mice were sacrificed and tumors processed for flow cytometry to evaluate immune cells present. Gated on Lymphocytes/Single Cells/Live/CD45+. Neutrophils = CD11b+ Ly6G+, Dendritic cells = CD11c+, macrophages/monocytes = CD11b+ Ly6C+, CD4 T cells = CD3+ CD4+, CD8 T cells = CD3+ CD8+, B cells = CD19+, and NK cells = NK1.1+. (B) Breakdown of immune cells within B16KVP or B16F10 subcutaneous tumors that received naïve pmel-1 ACT in addition to TBI. Same gating used as A. (C) Percentage of immune cells (CD45+) in B16KVP or B16F10 tumors six days after 5Gy TBI. Kruskal-Wallis test with multiple comparisons performed. (* denotes p < 0.05). (D) Percentage of host CD8+ T cells present in each tumor type +/- ACT. Gated on Lymphocytes/Single Cells/Live/CD45+. Kruskal-Wallis test with multiple comparisons performed. NS denotes p > 0.05. (E) Percentage of trp-2 tetramer positive host T cells present in the spleen, blood, and LN in long-term survivor mice 100+ days post-ACT. Gated on Lymphocytes/Live/Single Cells/CD45+/Thy1.1-Thy1.2+.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 6: Characterizing host immune cells in neoantigen versus wild-type tumors. (A) Breakdown of immune cells within B16KVP or B16F10 subcutaneous tumors (average taken of n=5). All mice were given either B16KVP or B16F10 tumors. Mice received TBI but no ACT. Five days later, mice were sacrificed and tumors processed for flow cytometry to evaluate immune cells present. Gated on Lymphocytes/Single Cells/Live/CD45+. Neutrophils = CD11b+ Ly6G+, Dendritic cells = CD11c+, macrophages/monocytes = CD11b+ Ly6C+, CD4 T cells = CD3+ CD4+, CD8 T cells = CD3+ CD8+, B cells = CD19+, and NK cells = NK1.1+. (B) Breakdown of immune cells within B16KVP or B16F10 subcutaneous tumors that received naïve pmel-1 ACT in addition to TBI. Same gating used as A. (C) Percentage of immune cells (CD45+) in B16KVP or B16F10 tumors six days after 5Gy TBI. Kruskal-Wallis test with multiple comparisons performed. (* denotes p < 0.05). (D) Percentage of host CD8+ T cells present in each tumor type +/- ACT. Gated on Lymphocytes/Single Cells/Live/CD45+. Kruskal-Wallis test with multiple comparisons performed. NS denotes p > 0.05. (E) Percentage of trp-2 tetramer positive host T cells present in the spleen, blood, and LN in long-term survivor mice 100+ days post-ACT. Gated on Lymphocytes/Live/Single Cells/CD45+/Thy1.1-Thy1.2+.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 3: Survival Analysis in the SKCM Cohort. (A) The top 10 genes that were significantly upregulated in neoantigen tumors day 5 post-ACT were evaluated for their impact on survival in the TCGA SKCM cohort. Overall Survival with a Median Group Cutoff was used. Hazards Ratio was calculated based on the PH model. 95% confidence interval is displayed as a dotted line. Graphs made using GEPIA.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 3: Survival Analysis in the SKCM Cohort. (A) The top 10 genes that were significantly upregulated in neoantigen tumors day 5 post-ACT were evaluated for their impact on survival in the TCGA SKCM cohort. Overall Survival with a Median Group Cutoff was used. Hazards Ratio was calculated based on the PH model. 95% confidence interval is displayed as a dotted line. Graphs made using GEPIA.